Skip to main content
Journal cover image

Population Pharmacokinetics of Piperacillin/Tazobactam Across the Adult Lifespan.

Publication ,  Journal Article
Hemmersbach-Miller, M; Balevic, SJ; Winokur, PL; Landersdorfer, CB; Gu, K; Chan, AW; Cohen-Wolkowiez, M; Conrad, T; An, G; Kirkpatrick, CMJ ...
Published in: Clin Pharmacokinet
January 2023

BACKGROUND AND OBJECTIVE: Piperacillin/tazobactam is one of the most frequently used antimicrobials in older adults. Using an opportunistic study design, we evaluated the pharmacokinetics of piperacillin/tazobactam as a probe drug to evaluate changes in antibacterial drug exposure and dosing requirements, including in older adults. METHODS: A total of 121 adult patients were included. The population pharmacokinetic models that best characterized the observed plasma concentrations of piperacillin and tazobactam were one-compartment structural models with zero-order input and linear elimination. RESULTS: Among all potential covariates, estimated creatinine clearance had the most substantial impact on the elimination clearance for both piperacillin and tazobactam. After accounting for renal function and body size, there was no remaining impact of frailty on the pharmacokinetics of piperacillin and tazobactam. Monte Carlo simulations indicated that renal function had a greater impact on the therapeutic target attainment than age, although these covariates were highly correlated. Frailty, using the Canadian Study of Health and Aging Clinical Frailty Scale, was assessed in 60 patients who were ≥ 65 years of age. CONCLUSIONS: The simulations suggested that adults ≤ 50 years of age infected with organisms with higher minimum inhibitory concentrations may benefit from continuous piperacillin/tazobactam infusions (12 g/day of piperacillin component) or extended infusions of 4 g every 8 hours. However, for a target of 50% fT + minimum inhibitory concentration, dosing based on renal function is generally preferable to dosing by age, and simulations suggested that patients with creatinine clearance ≥ 120 mL/min may benefit from infusions of 4 g every 8 hours for organisms with higher minimum inhibitory concentrations.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Pharmacokinet

DOI

EISSN

1179-1926

Publication Date

January 2023

Volume

62

Issue

1

Start / End Page

127 / 139

Location

Switzerland

Related Subject Headings

  • Tazobactam
  • Piperacillin, Tazobactam Drug Combination
  • Piperacillin
  • Pharmacology & Pharmacy
  • Penicillanic Acid
  • Microbial Sensitivity Tests
  • Longevity
  • Humans
  • Frailty
  • Creatinine
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hemmersbach-Miller, M., Balevic, S. J., Winokur, P. L., Landersdorfer, C. B., Gu, K., Chan, A. W., … Schmader, K. E. (2023). Population Pharmacokinetics of Piperacillin/Tazobactam Across the Adult Lifespan. Clin Pharmacokinet, 62(1), 127–139. https://doi.org/10.1007/s40262-022-01198-z
Hemmersbach-Miller, Marion, Stephen J. Balevic, Patricia L. Winokur, Cornelia B. Landersdorfer, Kenan Gu, Austin W. Chan, Michael Cohen-Wolkowiez, et al. “Population Pharmacokinetics of Piperacillin/Tazobactam Across the Adult Lifespan.Clin Pharmacokinet 62, no. 1 (January 2023): 127–39. https://doi.org/10.1007/s40262-022-01198-z.
Hemmersbach-Miller M, Balevic SJ, Winokur PL, Landersdorfer CB, Gu K, Chan AW, et al. Population Pharmacokinetics of Piperacillin/Tazobactam Across the Adult Lifespan. Clin Pharmacokinet. 2023 Jan;62(1):127–39.
Hemmersbach-Miller, Marion, et al. “Population Pharmacokinetics of Piperacillin/Tazobactam Across the Adult Lifespan.Clin Pharmacokinet, vol. 62, no. 1, Jan. 2023, pp. 127–39. Pubmed, doi:10.1007/s40262-022-01198-z.
Hemmersbach-Miller M, Balevic SJ, Winokur PL, Landersdorfer CB, Gu K, Chan AW, Cohen-Wolkowiez M, Conrad T, An G, Kirkpatrick CMJ, Swamy GK, Walter EB, Schmader KE. Population Pharmacokinetics of Piperacillin/Tazobactam Across the Adult Lifespan. Clin Pharmacokinet. 2023 Jan;62(1):127–139.
Journal cover image

Published In

Clin Pharmacokinet

DOI

EISSN

1179-1926

Publication Date

January 2023

Volume

62

Issue

1

Start / End Page

127 / 139

Location

Switzerland

Related Subject Headings

  • Tazobactam
  • Piperacillin, Tazobactam Drug Combination
  • Piperacillin
  • Pharmacology & Pharmacy
  • Penicillanic Acid
  • Microbial Sensitivity Tests
  • Longevity
  • Humans
  • Frailty
  • Creatinine